To explore the type, prevalence and outcomes in chronic myeloid leukaemia (CML) patients with uncommon BCR-ABL1 transcripts in the era of tyrosine kinase inhibitors (TKIs), uncommon BCR-ABL1 transcripts were screened in 4750 patients by multiplex polymerase chain reaction (PCR), and type-specific real-time quantitative PCR was regularly performed for molecular monitoring. A total of 19 uncommon transcripts, including e1a2, e1a3, e6a2, e8a2, e12a2, unusual e13a2, e13a3, unusual e14a2, e14a3 and e19a2 were identified in 83 (1Á7%) patients. The three most frequent types were e19a2, e13a3/ e14a3 and e1a2. Compared with the 571 newly diagnosed CML patients in chronic phase with common e13a2/e14a2 transcripts receiving frontline imatinib therapy, patients with the e19a2 (n = 16) and e1a2 (n = 11) transcripts had significantly reduced probabilities of 1-year complete cytogenetic response (CCyR, P = 0Á0004 and 0Á016) and major molecular response (MMR, P = 0Á0018 and 0Á0035), and patients with the e13a3/e14a3 transcript (n = 10) had significantly increased probabilities of 1-year CCyR (P = 0Á0072) and MMR (P = 0Á0073). Patients with the e19a2 transcript had low probabilities of 2-year event-free survival (EFS, P = 0Á0004) and progression-free survival (P = 0Á0067), and patients with the e1a2 transcript had low probability of 2-year EFS (P < 0Á0001). Therefore, uncommon BCR-ABL1 fusion transcripts are rare and diverse in patients with CML and may be relevant for TKI therapy outcomes.
Summary
To explore the type, prevalence and outcomes in chronic myeloid leukaemia (CML) patients with uncommon BCR-ABL1 transcripts in the era of tyrosine kinase inhibitors (TKIs), uncommon BCR-ABL1 transcripts were screened in 4750 patients by multiplex polymerase chain reaction (PCR), and type-specific real-time quantitative PCR was regularly performed for molecular monitoring. A total of 19 uncommon transcripts, including e1a2, e1a3, e6a2, e8a2, e12a2, unusual e13a2, e13a3, unusual e14a2, e14a3 and e19a2 were identified in 83 (1Á7%) patients. The three most frequent types were e19a2, e13a3/ e14a3 and e1a2. Compared with the 571 newly diagnosed CML patients in chronic phase with common e13a2/e14a2 transcripts receiving frontline imatinib therapy, patients with the e19a2 (n = 16) and e1a2 (n = 11) transcripts had significantly reduced probabilities of 1-year complete cytogenetic response (CCyR, P = 0Á0004 and 0Á016) and major molecular response (MMR, P = 0Á0018 and 0Á0035), and patients with the e13a3/e14a3 transcript (n = 10) had significantly increased probabilities of 1-year CCyR (P = 0Á0072) and MMR (P = 0Á0073). Patients with the e19a2 transcript had low probabilities of 2-year event-free survival (EFS, P = 0Á0004) and progression-free survival (P = 0Á0067), and patients with the e1a2 transcript had low probability of 2-year EFS (P < 0Á0001). Therefore, uncommon BCR-ABL1 fusion transcripts are rare and diverse in patients with CML and may be relevant for TKI therapy outcomes.
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The BCR-ABL1 fusion gene is the molecular hallmark of chronic myeloid leukaemia (CML) (Lugo et al, 1990) . More than 95% of CML patients have the typical P210-encoding BCR-ABL1 fusion gene resulting from either an e13a2 (b2a2) or e14a2 (b3a2) junction, and cases with uncommon BCR-ABL1 junctions, such as e19a2 and e1a2, are rare and may result in BCR-ABL1 being undetectable by routine polymerase chain reaction (PCR) (Saglio et al, 1990; Selleri et al, 1990; Melo, 1997) . Regular monitoring of BCR-ABL1 transcript levels by real-time quantitative PCR (RQ-PCR) has become an integral part of routine clinical management of CML in the tyrosine kinase inhibitor (TKI) era (Hughes et al, 2006) ; therefore, identifying the junction characteristics of the BCR-ABL1 fusion gene is necessary for performing appropriate RQ-PCR. Due to the fairly low incidence and high diversity of uncommon BCR-ABL1 fusion transcripts, thus far, only a limited number of cohort studies have reported the types and prevalence of uncommon BCR-ABL1 transcripts in CML patients (Ito et al, 2004; Goh et al, 2006; Pardanani et al, 2009; Verma et al, 2009; Todoric-Zivanovic et al, 2011; Gui et al, 2015; Arun et al, 2017) . Currently, many studies have revealed outstanding outcomes in CML patients with typical BCR-ABL1 transcripts (O'Brien et al, 2003; Baccarani et al, 2013) , and a few studies have reported relatively poor response to TKIs and dismal prognosis in patients with p190 BCR-ABL1 (Pardanani et al, 2009; Verma et al, 2009; Arun et al, 2017) . However, TKI therapy outcomes in patients with other uncommon BCR-ABL1 transcripts have not yet been well established.
To address these questions, we retrospectively reviewed more than 4000 CML patients who have been referred to our hospital in the past decade and explored the prevalence and outcomes of uncommon BCR-ABL1 transcripts in these patients.
Materials and methods

Patients
All patients with CML who underwent BCR-ABL1 transcript detection and who had detectable BCR-ABL1 at least once between January 2007 and October 2017 at our hospital were included in this study. Data of newly diagnosed patients in the chronic phase (CP) of CML with common e13a2/e14a2 transcripts and uncommon BCR-ABL1 transcripts who received imatinib, nilotinib or dasatinib therapy and who were regularly monitored based on the European LeukaemiaNet (ELN) recommendation were reviewed to compare the response to TKIs and outcomes (Baccarani et al, 2013) . The diagnosis and disease phase were based on World Health Organization criteria (Vardiman et al, 2008) . Cytogenetic responses were analysed every 3 or 6 months until a complete cytogenetic response (CCyR) was achieved and then analysed every 12 to 36 months. Molecular responses were assessed every 3 months until a major molecular response (MMR) was achieved and then assessed every 3 or 6 months. ABL1 tyrosine kinase domain mutations were screened in case of treatment failure or the presence of warning responses according to the ELN criteria (Soverini et al, 2011) . The study was approved by the Ethics Committee of Peking University People's Hospital, and all patients gave written informed consent to participate in the study in accordance with the Declaration of Helsinki.
PCR detection of BCR-ABL1
Peripheral blood (PB) or bone marrow (BM) samples were used to analyse BCR-ABL1 transcripts. Nucleated cells were obtained by treating fresh samples with 0Á144 M NH 4 Cl, 0Á01 M NH 4 HCO3 to lyse the red cells. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and a high-capacity cDNA reverse transcription kit (Invitrogen, Carlsbad, CA, USA) was used to synthesize cDNA. TaqMan-based RQ-PCR was performed for the detection of typical e13a2/e14a2 transcripts, as previously reported (Qin & Huang, 2016) . Multiplex RQ-PCR for the detection of every kind of BCR-ABL1 transcript included 6 forward primers that were situated at BCR exon 1, 6, 8, 11, 13 or 19 and 2 reverse primers and 2 TaqMan probes positioned at ABL1 exon 2 or 3. Multiplex RQ-PCR and RQ-PCR detection of typical BCR-ABL1 transcripts were simultaneously performed in patients undergoing BCR-ABL1 transcript analysis for the first time at our hospital. Discordant results implied the existence of uncommon BCR-ABL1 junctions.
Split-out qualitative PCR was then performed, and the PCR products subjected to Sanger sequencing. After uncommon BCR-ABL1 transcripts were identified and confirmed, typespecific RQ-PCR test was used for regular molecular monitoring during TKI therapy. Because a low level of the e1a2 transcript frequently coexists with common e13a2/e14a2 and may have no pathogenetic significance in CML (van Rhee et al, 1996) , we focused only on the sole e1a2 transcript and screened it out using this protocol. The uncommon e1a2 transcript in the current study refers to sole e1a2.
Definitions of response and outcome
In the current study, MMR was defined as BCR-ABL IS (BCR-ABL1 transcript levels on the international scale) ≤0Á1% in patients with common BCR-ABL1 transcripts and an individual ≥3 log reduction from the BCR-ABL1 transcript level at diagnosis in patients with uncommon BCR-ABL1 transcripts. Event-free survival (EFS) was defined as the time elapsed between the commencement of TKI therapy and the appearance of one of the following events: the absence of haematological response at 3 months; the loss of previously achieved complete haematological response (CHR), major cytogenetic response (MCyR) or CCyR; progression to accelerated phase (AP) or blast phase (BP); death from any cause, or the end of follow-up. Progression-free survival (PFS) was defined as the time elapsed between the commencement of TKI therapy and progression to AP or BP; death from any cause, or the end of follow-up. Overall survival (OS) was defined as the time elapsed between the commencement of TKI therapy and death from any cause or the end of follow-up. Patients who received allogeneic stem cell transplantation (allo-HSCT) were censored at the time of their transplantation.
Statistical analyses
Cumulative probabilities of CCyR and MMR were calculated by considering the competing risks defined by death. Comparisons between cumulative probabilities were performed by the Gray test. Survival functions were estimated using the Kaplan-Meier method and compared by the log-rank test. All statistical analyses were performed with R version 2.6.1 (The R Foundation for Statistical Computing, Vienna, Austria), SPSS 13.0 (SPSS Inc., Chicago, IL, USA), and GraphPad Prism5 software (GraphPad Software Inc., La Jolla, CA, USA).
Results
Frequencies of uncommon BCR-ABL1 transcripts
A total of 4750 CML patients with detectable BCR-ABL1 underwent BCR-ABL1 fusion transcript detection at least once, of which 4667 (98Á3%) patients had e13a2/e14a2 (P210) BCR-ABL1 fusion transcripts, and 83 (1Á7%) had uncommon BCR-ABL1 junctions. The three most frequent Y.-Z. Qin et al transcript types were e19a2, e13a3/e14a3 and e1a2, which accounted for 39Á8%, 20Á5% and 16Á9% of cases with uncommon BCR-ABL1 transcripts, respectively (Fig 1) . These represented three-quarters of the cases with uncommon BCR-ABL1 transcripts, and the rest were e1a3, e6a2, e8a2, e12a2, unusual e13a2 and unusual 14a2.
Sequence characteristics of uncommon BCR-ABL1 transcripts
Sanger sequencing showed the presence of 19 types of uncommon BCR-ABL1 fusion transcripts in total; all of them were in-frame, and 13 had never been reported before. The sequence characteristics were as follows:
1 Five transcripts including e1a2, e1a3, e13a3, e14a3 and e19a2. Both BCR and ABL1 exons at the junction site were intact, and no other sequences were inserted. These types were identified in 65 patients. 2 e6a2. Representing 2 types -one type had intact BCR exon 6 and ABL1 exon 2 sequences identified in 2 patients. The other type had a complex insertion comprising a 38-bp inverted BCR intron 5 followed by a 58-bp inverted ABL1 intron 1b, identified in 1 patient. 3 e8a2. Representing 4 types -all had intact ABL1 exon 2 and sequence insertions at the junction site, and 2 had intact BCR exon 8. One type had the identical 55-bp inverted ABL1 intron 1b insertion and intact BCR exon 8 (e8-int1b-a2) as previously reported (Fig 2A, GenBank accession number: AB 069693) and was identified in 4 patients. Two types had different lengths of the 5 0 region of BCR exon 8 and had a 16-bp ABL1 intron 1a or intron 1b insertion and were identified in 2 patients. The other type had intact BCR exon 8 and an insertion from the DRG1 (developmentally regulated GTP binding protein 1) gene exon 4 with a combination of un-inverted 70-bp and inverted 23-bp (Fig 2B) insertion. This type was identified in 1 patient. 4 e12a2. Both BCR exon 12 and ABL1 exon 2 were intact, and there was an 18-bp ABL1 intron 1b insertion at the junction site (Fig 2C) . This type was identified in 1 patient. 5 Unusual e13a2 transcripts. Representing 6 types and individually identified in 1 patient. All had intact ABL1 exon 2 and different lengths of the 5 0 region of BCR exon 13. Furthermore, 5 types had sequence insertions at the junction site -2 had the same 59-bp ABL1 intron 1b insertion but a 51-bp difference in the length of BCR exon 13 (Fig 2D, PTN 1 and PTN 2); 1 had a 23-bp ABL1 intron 1b insertion; 1 had a combined insertion of a 22-bp ABL1 intron 1a and a 6-bp fragment in the 3 0 region of ABL1 1a; and 1 had a 9-bp insertion from ABL1 intron 3. 6 Unusual e14a2 transcript. This transcript had intact BCR exon 14 and ABL1 exon 2, and the 12-bp sequence from the 5 0 region of ABL1 exon 2 was inverted (Fig 2E) . This type was identified in 1 patient. 
Characteristics of patients with uncommon BCR-ABL1 transcripts at diagnosis
Among the 83 patients with uncommon BCR-ABL1 transcripts, 48 (58%) were male, and the median age at diagnosis was 43 years (range, 16-87). Among the 81 evaluable patients, 75 (93%) and 6 (7%) patients were in CP and AP at diagnosis, respectively. The demographic and laboratory characteristics at diagnosis in patients with CP CML with the three most frequent uncommon transcripts are presented in Table I . In addition, 701 newly diagnosed CP CML patients during the same period who had the common e13a2/e14a2 transcript received TKI therapy and were regularly monitored as controls for comparison. There were some differences among the 4 cohorts. Patients with the e1a2 transcript were much older (P = 0Á0013) and had lower platelet counts (P = 0Á028) than patients with common transcripts. Additionally, patients with the e19a2 transcript had lower proportions of males (P = 0Á020), higher platelet counts (P = 0Á036) and higher Sokal risk score (11/20 vs. 115/611, 55% vs .19%, P = 0Á0004) than patients with common transcripts; however the distribution of Sokal risk scores was similar among patients with e1a2, e13a3/e14a3 and e13a2/e14a2 transcripts (1/8 vs. 1/8 vs. 115/611, 13% vs. 13% vs. 19%, P = 0Á47). Sequences at the junction site of the 5 uncommon BCR-ABL1 transcripts. A: Sequencing chromatogram of the identical 55-bp inverted ABL1 intron 1b insertion between the intact BCR exon 8 and ABL1 exon 2 junction in 4 patients; B: e8a2 with a sequence insertion from the DRG1 gene; C: e12a2 with an insertion from ABL1 intron 1b; D: e13a2 with an insertion from ABL1 intron 1b; BCR exon 13 at the junction site is 51 bp longer in PTN 1 than that in PTN 2; E: e14a2 with an inverted 12-bp sequence at the 5 0 region of ABL1 exon 2. [Colour figure can be viewed at wileyonlinelibrary.com]
Responses and outcomes in newly diagnosed patients in CP with uncommon BCR-ABL1 transcripts receiving imatinib therapy
A total of 43 newly diagnosed patients with CML in CP with uncommon transcripts received frontline imatinib therapy and were regularly monitored. Among them, 37 had the e1a2 (n = 11), e13a3/e14a3 (n = 10) or e19a2 (n = 16) transcript. Additionally, 571 newly diagnosed patients in CP with the common transcript who received imatinib therapy and were regularly monitored during the same period were used as controls. Because RQ-PCR for uncommon BCR-ABL1 transcripts cannot be performed in the majority of Chinese laboratories, the proportion of the patients with uncommon transcripts in this follow-up cohort was higher than that of the whole CML cohort. Patients with the e19a2 or e1a2 transcript had significantly lower probabilities of 1-year CCyR [44Á4%, 95% confidence interval (CI): 17Á7-68Á3% vs. 87Á9%, 95% CI: 86Á6-89Á1%; P = 0Á0004 and 58Á0%, 95% CI: 24Á5-82Á2% vs. 87Á9%, 95% CI: 86Á6-89Á1%; P = 0Á016] and MMR (6Á3%, 95% CI: 0-67Á7% vs. 48Á6%, 95% CI: 44Á2-52Á9%; P = 0Á0018 and 0% vs. 48Á6%, 95% CI: 44Á2-52Á9%; P = 0Á0035) than patients with common transcripts (Fig 3) ; however, patients with the e13a3/e14a3 transcript had significantly higher 1-year CCyR and MMR rates (100% vs. 87Á9%, 95% CI: 86Á6-89Á1%; P = 0Á0072 and 83Á3%, 95% CI: 62Á1-93Á2% vs. 48Á6%, 95% CI: 44Á2-52Á9%; P = 0Á0073) patients with common transcripts. With a median follow-up of 23 (range, 3-115) months, patients with the e19a2 transcript had lower probabilities of 2-year EFS (69Á1%, 95% CI: 36Á1-87Á5% vs. 94Á4%, 95% CI: 92Á0-96Á1%; P = 0Á0004) and PFS (76Á6%, 95% CI: 42Á6-92Á0% vs. 95Á7%, 95% CI: 93Á5-97Á2%; P = 0Á0067), than patients with the common transcript. Furthermore, patients with the e1a2 transcript had Table I . Characteristics of chronic myeloid leukaemia patients in chronic phase with the three most uncommon BCR-ABL1 transcripts and the common BCR-ABL1 transcript at diagnosis. Response to imatinib therapy in newly diagnosed patients in the chronic phase of CML. A: Cumulative probability of complete cytogenetic response (CCyR). The 1-year CCyR rates were 58Á0%, 95% CI: 24Á5-82Á2%; 100%, 95% CI: 100-100%; 44Á4%, 95% CI: 17Á7-68Á3%; and 87Á9%, 95% CI: 86Á6-89Á1% in patients with e1a2, e13a3/e14a3, e19a2 and e13a2/e14a2 transcripts, respectively. B: Cumulative probability of major molecular response (MMR). The 1-year MMR rates were 0%, 95% CI: 0-0%, 83Á3%; 95% CI: 62Á1-93Á2%; 6Á3%, 95% CI: 0-67Á7%; and 48Á6%, 95% CI: 44Á2-52Á9% in patients with e1a2, e13a3/e14a3, e19a2 and e13a2/e14a2 transcripts, respectively. TKI, tyrosine kinase inhibitor.
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ª 2018 British Society for Haematology and John Wiley & Sons Ltd lower 2-year EFS rates (30Á3%, 95% CI: 1Á0-73Á4% versus 94Á4%, 95% CI: 92Á0-96Á1%; P < 0Á0001) than patients with the common transcript but similar PFS rate (90Á9%, 95% CI: 50Á8-98Á5% vs. 95Á7%, 95% CI: 93Á5-97Á2%; P = 0Á28; Fig 4) . However, patients with the e13a3/e14a3 transcript had similar outcomes as patients with common transcripts (EFS: P = 0Á44; PFS: P = 0Á46). There was no difference in OS among the 4 cohorts (P = 0Á45). In the remaining 6 patients with uncommon transcripts (e8a2, n = 3; e6a2, n = 1; unusual e13a2, n = 1; and unusual e14a2, n = 1), 5 patients (83%) achieved a CCyR at 3-12 months, and 3 (50%) achieved an MMR at 12-24 months in response to imatinib therapy. The patient with the e6a2 transcript did not achieve a CHR at 3 months and progressed to BP at 6 months on imatinib therapy.
Responses and outcomes of newly diagnosed patients with CML in CP with uncommon BCR-ABL1 transcripts receiving second-generation TKI therapy
Five patients with the e19a2 transcript received nilotinib (n = 3) or dasatinib (n = 2) as frontline therapy. One of these five patients had an intermediate Sokal risk score, and 3 had high Sokal risk scores. Four patients achieved a CCyR at 3-6 months, and 2 of them had undetectable BCR-ABL1 transcripts at 9 months, and these responses were maintained thereafter at a median follow-up of 9 (range, 0-12) months. One patient had no cytogenetic response (100% of Ph chromosome) until 9 months and developed a T315I mutation in response to dasatinib treatment. This patient was switched to ponatinib and maintained a continuous CHR with 100% Ph chromosome for 6 months and then received allo-HSCT. One patient with the e1a2 transcript achieved a CCyR at 9 months on nilotinib therapy and maintained CCyR thereafter. This patient did not achieve an MMR during the follow-up period of 24 months.
Discussion
In the current study, we identified 83 patients (1Á7%) with 19 types of uncommon BCR-ABL1 transcripts from a relatively large population of CML patients; 13 of these uncommon BCR-ABL1 transcripts had never been reported before. Among the uncommon BCR-ABL1 transcripts, the most frequent types were e19a2, followed by e13a3/e14a3 and e1a2. Regarding the responses and outcomes in newly diagnosed CML patients in CP with the uncommon BCR-ABL1 transcripts receiving frontline imatinib therapy, patients with the e19a2 or e1a2 transcript were associated with lower probabilities of 1-year CCyR and MMR and 2-year EFS, whereas patients with the e13a3/ e14a3 transcript were associated with higher CCyR and MMR rates than patients with the common e13a2/e14a2 transcript.
A vast majority of CML patients have the typical e13a2 and/or e14a2 BCR-ABL1 junction. Several studies with large sample sizes have shown that the frequency of the common e13a2/e14a2 transcript in CML was 97Á7% to 98Á5% (Ito et al, 2004; Goh et al, 2006; Todoric-Zivanovic et al, 2011; Arun et al, 2017) , consistent with our findings (98Á3%). The e1a2, e19a2 and e13a3/e14a3 transcripts were the most commonly reported types in previous studies (Goh et al, 2006; Arun et al, 2017 ) and the present study. In addition to these 3 types of transcripts, we identified e1a3, e6a2, e8a2, e12a2 and unusual e13a2/e14a2 and found that the three most frequent types accounted for three-quarters of the cases with uncommon BCR-ABL1 transcripts.
To guarantee that ABL1 protein-coding sequence is kept in-frame, breakpoint may occur within the BCR exon, and a sequence insertion may take place. In such cases, the breakpoint within the BCR exon and the inserted sequence are usually unique, as reported in previous studies (Sorel et al, 2010; Huet et al, 2015) . In the current study, in addition to transcripts e19a2, e13a3/e14a3 and e1a2, 15 different fusion transcripts were identified in 19 patients. Moreover, the
Outcomes in response to imatinib therapy in newly diagnosed patients in the chronic phase of CML. A: Event-free survival (EFS). The 2-year EFS rates were 30Á3%, 95% CI: 1Á0-73Á4%; 100%, 95% CI: 100-100%; 69Á1%, 95% CI: 36Á1-87Á5%; and 94Á4%, 95% CI: 92Á0-96Á1% in patients with e1a2, e13a3/e14a3, e19a2 and e13a2/e14a2 transcripts, respectively. B: Progression-free survival (PFS). The 2-year PFS rates were 90Á9%, 95% CI = 50Á8-98Á5%; 100%, 95% CI: 100-100%; 76Á6%, 95% CI: 42Á6-92Á0%; and 95Á7%, 95% CI: 93Á5-97Á2% in patients with e1a2, e13a3/e14a3, e19a2 and e13a2/e14a2 transcripts, respectively. C: Overall survival (OS). The 2-year OS rates were 100%, 95% CI: 100-100% in patients with e1a2, e13a3/e14a3, e19a2 transcripts and 98Á4%, 95% CI: 96Á8-99Á2% in patients with e13a2/e14a2 transcripts. TKI: tyrosine kinase inhibitor.
uniform e8-int1b-a2 type, which was identical to the sequence in previous reports (Branford et al, 2000; Sugimoto et al, 2004) , was found in 4 patients. This reproducibility implied that the gene fusion is not totally stochastic and that the e8-int1b-a2-encoded BCR-ABL1 protein may have high leukaemogenic potential. Thus far, over 50 CML patients with the e19a2 transcript have been reported, and 19 of them received TKI therapy, but the responses and outcomes on imatinib therapy were ambiguous (Saglio et al, 1990; Ikeda et al, 2016; Sazawal et al, 2017 ). In the current study, we identified 33 patients with the e19a2 transcript, who had significantly higher probability of high Sokal risk scores at diagnosis and significantly lower probabilities of CCyR, MMR, EFS and PFS than patients with common BCR-ABL1 transcripts in response to frontline imatinib therapy, whereas 5 patients with the e19a2 transcript seem to have better responses to second generation TKIs. These findings suggested that patients with the e19a2 transcript could be treated with second generation TKIs as first-line therapy to improve treatment responses and outcomes.
To date, limited studies have reported totally approximately 20 cases with the e13a3/e14a3 transcript, with obscure responses and outcomes in the TKI era (Gui et al, 2015; Ha et al, 2016; Duan et al, 2017 ). In the current study, 17 patients with the e13a3/e14a3 transcript showed similar clinical characteristics at diagnosis but better treatment responses and outcomes to imatinib therapy than patients with common BCR-ABL1 transcripts. Compared with common e13a2/ e14a2 transcript, e13a3/e14a3 only deleted ABL1 exon 2, which encodes part of the SH3 region. The role of the SH3 domain in leukaemogenesis is still controversial and remains to be investigated (Skorski et al, 1998; Smith et al, 2003) .
Previous studies have reported that CML patients with the e1a2 transcript were associated with inferior outcomes to TKI therapy, especially imatinib therapy (Pardanani et al, 2009; Verma et al, 2009; Arun et al, 2017) , consistent with our findings. Thus, CML patients with the e1a2 transcript might be recommended to receive 2nd generation TKI as first-line therapy.
There are several limitations in the current study. First, it is a retrospective study, and some patients did not have complete information at diagnosis and during follow-up. Second, multivariate analyses could not be performed to analyse the potential interaction of other variables with BCR-ABL1 transcript types and their overall impact on outcomes due to the relatively small sample size of each uncommon transcript type. Third, the e13a2 and e14a2 transcripts were not differentiated in our routine testing, leaving us unable to make individual comparisons.
In conclusion, uncommon BCR-ABL1 fusion transcripts are rare and diverse in patients with CML and may be relevant for TKI therapy outcomes. Patients with the e19a2 or e1a2 transcript had poor treatment outcomes; however, patients with the e13a3/e14a3 transcript had better outcomes to imatinib therapy than patients with the common e13a2/e14a2 transcripts. Therefore, uncommon BCR-ABL1 transcripts need to be identified at presentation to aid in diagnosing, appropriate monitoring and guiding treatment choices for patients with CML. The findings of the current study need to be confirmed in future studies with a larger population. The accumulation of such cases with uncommon BCR-ABL1 transcripts by multicentre cooperation is crucial to fully and comprehensively clarify their prognostic significance in the TKI era.
